I recently read an interesting article in *Diabetes Care* ([@B1]) that showed that treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors could be associated with a reduced risk of bone fractures in type 2 diabetic patients. As the authors pointed out, since experimental data in animal models suggested that incretins such as glucagon-like peptide-1 (GLP-1) and gastric intestinal polypeptide (GIP) stimulated bone formation and increased bone density ([@B2]), it is conceivable that DPP-4 inhibitors could exert beneficial effects on the bone by increasing the levels of incretins. However, bone density is increased rather than decreased in type 2 diabetes ([@B3]). So, bone quality may be more important than bone density in defining the increased risk for fractures in type 2 diabetic patients.

There is accumulating evidence that advanced glycation end products (AGEs) could play a role in impaired bone quality in type 2 diabetes ([@B4]). Indeed, despite normal bone mineral density, bone mechanical properties were impaired in spontaneous diabetic rats, which coincided with the increased content of pentosidine, one of the well-characterized AGEs in the bone collagen ([@B4]). Serum pentosidine level was associated with the presence of vertebral fractures in postmenopausal type 2 diabetic women independent of bone density and other risk factors for osteoporosis ([@B4]). Urinary pentosidine level was also associated with both increased clinical fracture incidence and vertebral fracture prevalence in elderly patients with type 2 diabetes ([@B4]). Further, AGEs not only inhibited the proliferation and differentiation of osteoblasts but also induced activation of osteoblasts through the interaction with their receptor, RAGE ([@B4]). Mice lacking RAGE had increased bone density and biomechanical strength and decreased number of osteoclasts and bone resorptive activity ([@B4]). These observations suggest that the AGE-RAGE axis may be involved in reduced bone density as well, thus contributing to an increased risk of bone fractures in type 2 diabetes.

We have previously shown that GLP-1 and GIP reduce RAGE expression in endothelial and mesangial cells through the elevation of cyclic AMP levels and resultantly block the deleterious effects of AGEs in vitro ([@B5]). Further, we have recently found that treatment with vildagliptin, an inhibitor of DPP-4, suppresses the formation and accumulation of AGEs and reduces the expression levels of RAGE in thoracic aorta of type 2 diabetic rats with obesity, thus suggesting that DPP-4 inhibitors could play a protective role against vascular injury in type 2 diabetes partly by attenuating the harmful effects of the AGE-RAGE axis ([@B5]). Therefore, the AGE-RAGE axis in the bone may also be a molecular target of DPP-4 inhibitors. It would be interesting to examine whether a reduced risk of bone fractures in type 2 diabetic patients with DPP-4 inhibitors is actually associated with increased bone density or correlated with decreased serum or urinary level of pentosidine. These data help us to understand how DPP-4 inhibitors could protect against bone fractures in type 2 diabetic patients.
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